Publication Date

Spring 2015


Glymbasi is a drug designed from empagliflozin and linagliptin, two well-known and used antidiabetic drugs used to treat type-2 diabetes. This newly designed drug combines the two mechanisms of these drugs to co-administer simultaneous glycemic control on all fronts to provide a more effective and efficient treatment for type 2 diabetics . Glyxambi was created by combining appropriate dosages of emagliflozin and linagliptin into a single tablet for once daily use. This drug is now available for physicians to administer to their patients because companies such as BIPI and Eli Lilly have pooled their resources to provide more effective treatment options for this disease.


Chemistry 205


Copyright is owned by the creator of this work.

references for glyxambi poster.pdf (166 kB)
References used for Glyxambi poster



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.